Inventiva's Liquidity Contract with Kepler Cheuvreux: Half-Year Update

Inventiva, a clinical-stage biopharmaceutical company focused on developing therapies for steatohepatitis (MASH), has provided a half-year review of its liquidity contract with Kepler Cheuvreux. As of December 31, 2025, the liquidity account held €526,751.56 in cash, with 58,515 shares available. During the semester, 2,332 buy-side executions resulted in 550,198 shares traded for €2,093,559.19, while 2,741 sell-side executions traded 576,215 shares for €2,189,327.66.

Comparing the previous half-year, as of June 30, 2025, the account held €428,212.57 and 84,532 shares. The buy-side saw 1,642 executions with 267,584 shares traded for €744,692.94, and the sell-side had 1,878 executions with 296,504 shares traded for €819,771.51.